Gunilla Movin-Osswald
AstraZeneca (United Kingdom)(GB)AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Schizophrenia research and treatment, Cardiovascular Syncope and Autonomic Disorders, Bipolar Disorder and Treatment, Neurotransmitter Receptor Influence on Behavior, Growth Hormone and Insulin-like Growth Factors
Most-Cited Works
- → Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.(1995)48 cited
- → Remoxipride: pharmacokinetics and effect on plasma prolactin.(1991)21 cited
- → Pharmacokinetics of Raclopride Formulations(1992)15 cited
- → The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function.(1993)12 cited
- → Comparison of the agonist‐antagonist interaction model and the pool model for the effect of remoxipride on prolactin(2010)11 cited
- → Influence of the dosing interval on prolactin release after remoxipride.(1995)10 cited
- → Influence of rate of administration of raclopride on akathisia and prolactin response(1994)6 cited
- An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.(1995)
- → An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients(1993)4 cited
- Pharmacokinetics and pharmacodynamics of the neuroleptics remoxipride and raclopride - with special emphasis on prolactin response(1994)